Imaging as a Means of Studying Chemotherapy-Related Cognitive Impairment
The chemotherapy-related cognitive impairment (chemo fog/chemo brain) that is reported by many cancer patients is supported to varying degrees primarily by evidence from prospective and retrospective clinical studies. However, the inherent difficulty in conducting such trials (including ethical issues of placebo-controlled designs), the fact that the cognitive impairment is characteristically subtle and that the patients might be able to compensate for their deficits during testing, gives rise to questions about the degree and the extent of the problem—and indeed even if there is a problem. Neuroimaging techniques might offer additional insight. This chapter is a succinct summary of a more expanded review of the relatively few such studies.1
KeywordsBreast Cancer Adjuvant Chemotherapy Clin Oncol Breast Cancer Survivor Standardize Neuropsychological Test
Unable to display preview. Download preview PDF.
- 1.Raffa RB. Is a picture worth a thousand (forgotten) words?: neuroimaging evidence for the cognitive deficits in ‘chemo-fog’/‘chemo-brain’. J Clin Pharm Ther, in press..Google Scholar
- 27.Stemmer SM, Stears JC, Burton BS et al. White matter changes in patients with breast cancer treated with high-dose chemotherapy and autologous bone marrow support. Amer J Neuroradiol 1994; 15:1267–1273.Google Scholar
- 28.Brown MS, Simon JH, Stemmer SM et al. MR and proton spectroscopy of white matter disease induced by high-dose chemotherapy with bone marrow transplant in advanced breast carcinoma. Amer J Neuroradiol 1995; 16:2013–2020.Google Scholar
- 29.Brown MS, Stemmer SM, Simon JH et al. White matter disease induced by high-dose chemotherapy: longitudinal study with MR imaging and proton spectroscopy. Amer J Neuroradiol 1998; 19:217–221.Google Scholar